Cancer Cell-Intrinsic Type I Interferon Signaling Promotes Antitumor Immunity in Head and Neck Squamous Cell Carcinoma
Open Access
Abstract
Background: The cyclic GMP-AMP synthase (cGAS)–type I interferon (IFN-I) pathway detects cytoplasmic DNA and triggers immune responses. Cancer cells often suppress this pathway to evade immune surveillance; however, its therapeutic potential remains unclear. Methods: Mouse oral squamous cell carcinoma models, representing a prominent subtype of head and neck squamous cell carcinoma (HNSCC), were employed in this study. Flow cytometry, Western blot, ELISA, and PCR were used for analysis. Results: We found that immune-unresponsive MOC2 tumors exhibited a deficiency of antigen-presenting cells and cytotoxic T lymphocytes, along with a significant suppression of the cGAS-IFN-I pathway, compared to immune-responsive MOC1 tumors. An MOC2-conditioned medium impaired the differentiation of bone marrow-derived cells into dendritic cells (DCs), reducing the expression of DC markers as well as class I and II major histocompatibility complex (MHC) molecules. The activation of the cGAS-IFN-I pathway in MOC2 cells, either through exogenous DNA or direct IFN-I expression, enhanced class I MHC expression and antigen presentation on MOC2 cells. Furthermore, IFNB1 expression in MOC2 cells induced apoptosis and upregulated chemokines, such as CXCL9 and CXCL10, which recruit immune cells. In immunocompetent mice, IFNB1 expression suppressed MOC2 tumor growth by attracting DCs and T cells, an effect amplified by co-expressing the granulocyte–macrophage colony-stimulating factor. Conclusions: These findings highlight the potential of enhancing cancer cell-intrinsic cGAS-IFN-I signaling to improve tumor immune surveillance and control the progression of immune-cold HNSCC tumors.Keywords
Funding Information
- American Cancer Society Diversity in Cancer Research Institutional Development Grant at Howard University (DICRIDG-21-074-01)
- Georgetown–Howard Universities Center for Clinical and Translational Science (GHUCCTS) (DICRIDG-21-074-01)
- National Institute of Health R25DE032527 (DICRIDG-21-074-01)
- Howard University (DICRIDG-21-074-01)
This publication has 51 references indexed in Scilit:
- Bispecific dendritic-T cell engager potentiates anti-tumor immunityCell, 2024
- A distinct stimulatory cDC1 subpopulation amplifies CD8+ T cell responses in tumors for protective anti-cancer immunityCancer Cell, 2023
- Type I interferon activates MHC class I-dressed CD11b+ conventional dendritic cells to promote protective anti-tumor CD8+ T cell immunityImmunity, 2022
- Cancer-Cell-Intrinsic cGAS Expression Mediates Tumor ImmunogenicityCell Reports, 2019
- The Multifaceted Role of Chromosomal Instability in Cancer and Its MicroenvironmentCell, 2018
- Extrinsic Phagocyte-Dependent STING Signaling Dictates the Immunogenicity of Dying CellsCancer Cell, 2018
- Inactivation of Interferon Receptor Promotes the Establishment of Immune Privileged Tumor MicroenvironmentCancer Cell, 2017
- Pools of programmed death‐ligand within the oral cavity tumor microenvironment: Variable alteration by targeted therapiesHead & Neck, 2016
- Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and ProgressionCell Reports, 2016
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014